Innate's MIS416 fails in Phase IIb for MS

Innate Immunotherapeutics Ltd. (ASX:IIL) reported top-line data from a double-blind, Australian and New Zealand Phase IIb trial in 93 patients with secondary progressive multiple sclerosis (MS) showing that once-weekly 500 μg IV MIS416 for 52 weeks missed the primary endpoint of improving various measures of neuromuscular function vs. placebo. MIS416 also missed the secondary endpoints of improving Expanded Disability Status Scale (EDSS), MS Impact Scale (MSIS-29), Neurological Fatigue Index for MS (NFI-MS) and Brief Pain Inventory (BPI) scores vs. placebo. Additionally, there was no significant difference between treatment groups in the percent change in brain volume as measured by MRI.

The company said its compassionate use program of MIS416 will continue pending the results of further analysis...